Patents by Inventor James B. Lorens

James B. Lorens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9040462
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 26, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • Patent number: 8574827
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: November 5, 2013
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Robert E. Atchison, Annabelle Friera, Sacha Holland
  • Patent number: 7485414
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: February 3, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger, Sacha Holland
  • Publication number: 20080261819
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Application
    Filed: May 12, 2008
    Publication date: October 23, 2008
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • Patent number: 7419779
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Grant
    Filed: September 2, 2003
    Date of Patent: September 2, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Jakob Bogenberger, Sacha Holland, Weiduan Xu
  • Patent number: 7378248
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: May 27, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • Patent number: 7252952
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: August 7, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd M. Kinsella, Todd Pray, Mark K. Bennett
  • Patent number: 7244576
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein (“ILKAP”) and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: July 17, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Weiduan Xu, Robert E. Atchison, Jakob Bogenberger
  • Publication number: 20040053233
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 18, 2004
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger, Sacha Holland
  • Publication number: 20040002056
    Abstract: The invention relates to cells transformed with self-inactivating retroviral vectors and their use in methods of screening for candidate bioactive agents that produce an altered phenotype in the cells.
    Type: Application
    Filed: May 15, 2002
    Publication date: January 1, 2004
    Inventors: James B. Lorens, David A. Ferrick
  • Publication number: 20030176333
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding contactin associated protein 3 (CASPR3), which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of CASPR3; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: March 18, 2002
    Publication date: September 18, 2003
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger
  • Publication number: 20030099932
    Abstract: The invention relates to retroviral vectors comprising fusion nucleic acids useful for expressing a plurality of separate proteins products encoded by genes of interest. The invention further relates to use of the compositions in methods for screening for candidate agents producing an altered phenotype in cells.
    Type: Application
    Filed: May 3, 2002
    Publication date: May 29, 2003
    Inventors: James B. Lorens, David A. Ferrick
  • Publication number: 20020156003
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein (“ILKAP”) and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.
    Type: Application
    Filed: August 21, 2001
    Publication date: October 24, 2002
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Robert E. Atchison, Jakob Bogenberger